Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data

At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.